About Kryptos Biotechnologies
Kryptos Biotechnologies is a Healthcare company based in Hayward (United States) founded in 2017 by Jinyong Lee and Jun Ho Son. Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology. Kryptos Biotechnologies has raised $12.7 million across 3 funding rounds from investors including HHS, OSANG Healthcare and FuturePlay. Its chief executive, as recorded, is Jun Ho Son. Kryptos Biotechnologies offers products and services including Infectious Disease Diagnostics and Life Science Solutions. Its focus areas include Diversified Diagnostics, Life Sciences, Genomics and Applied Genomics. Its legal entity is Kryptos Biotechnologies, Inc. Its competitors include Inflammatix, Karius and Visby Medical; 3 of its 3 listed competitors have raised funding.
Company details
Kryptos Biotechnologies was founded in 2017 and is based in Hayward, United States. Operations focus on the biotechnology sector, where a point-of-care molecular diagnostic platform is developed and provided. The platform relies on Ultrafast Photonic PCR, which employs photothermal heating through plasmonic thin films driven by light-emitting diodes. Applications include diagnostics for infectious diseases, cardiac conditions, cancer, neurological disorders, and biowarfare pathogen detection at the point-of-care.
- Headquarters Hayward, United States
- Founders Jinyong Lee, Jun Ho Son
- SectorsHealthcare
- Email••••••••
- Website kryptosbio.com
- Legal Name Kryptos Biotechnologies, Inc.
- Total Equity Funding$12.7M (USD)
in 3 rounds
- Latest Funding Round$10M (USD), Series A
Mar 2024
- InvestorsHHS
& 4 more
Products & Services of Kryptos Biotechnologies
Kryptos Biotechnologies offers a comprehensive portfolio of products and services, including Infectious Disease Diagnostics and Life Science Solutions.
Offers PCR-based testing for point-of-care infectious disease detection.
Provides innovative analytical systems for healthcare and scientific applications.
Funding Insights of Kryptos Biotechnologies
Kryptos Biotechnologies has successfully raised a total of $12.7M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.7M
- Total Rounds 3
- Last Round Series A — $10M
- First Round $198,286
(Sep 2017)
- Investors Count 5
All 3 funding rounds of Kryptos Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $10M | Series A | – | OSANG Healthcare | – |
| Nov 2019 | $2.7M | Seed | – | FuturePlay, Coolidge Corner Investment | – |
| Sep 2017 | $198,286 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Kryptos Biotechnologies
Kryptos Biotechnologies has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, OSANG Healthcare and FuturePlay.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
FuturePlay is engaged in startup investment and acceleration. | futureplay.co | Seoul, South Korea | ||
| ccvc.co.kr | ||||
Offers financial services including auto loans, corporate finance, and investments to customers. | 1972 | kdbc.co.kr | Seoul, South Korea | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Diagnostic instruments for POC and central labs are developed. | 1996 | osanghc.com | Anyang, South Korea |
Investor details for Kryptos Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kryptos Biotechnologies
3 people are tracked at Kryptos Biotechnologies (3 in leadership).
| Name | Role | Group |
|---|---|---|
Jinyong Lee | Co-Founder & COO | Leadership |
Jun Ho Son | Co-Founder & CEO | Leadership |
Juliet Carrara | VP Qa/ra | Leadership |
Complete people profiles for Kryptos Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kryptos Biotechnologies
3 dated milestones of Kryptos Biotechnologies across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Kryptos Biotechnologies is founded.
- Funding First funding round of $198K.
- Funding Latest funding round, Series A, of $10.0M.
Competitors of Kryptos Biotechnologies
Kryptos Biotechnologies has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Karius and Visby Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. |
Detailed competitors of Kryptos Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kryptos Biotechnologies
The website of Kryptos Biotechnologies (kryptosbio.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 369.2% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Kryptos Biotechnologies (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kryptos Biotechnologies
Complete news archive for Kryptos Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kryptos Biotechnologies
Kryptos Biotechnologies was founded in 2017.
Kryptos Biotechnologies is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Jun Ho Son is the CEO of Kryptos Biotechnologies, as recorded in our data. They have also founded this company.
Kryptos Biotechnologies is a funded company, having raised a total of $12.7M across 3 funding rounds to date. The company's 1st funding round was a Grant of $198.29K, raised on Sep 2017.
Kryptos Biotechnologies was founded in 2017 and is based in Hayward, United States. Operations focus on the biotechnology sector, where a point-of-care molecular diagnostic platform is developed and provided. The platform relies on Ultrafast Photonic PCR, which employs photothermal heating through plasmonic thin films driven by light-emitting diodes. Applications include diagnostics for infectious diseases, cardiac conditions, cancer, neurological disorders, and biowarfare pathogen detection at the point-of-care.
Kryptos Biotechnologies's top competitors include Visby Medical, Inflammatix and Karius.
Kryptos Biotechnologies offers Infectious Disease Diagnostics and Life Science Solutions.
Kryptos Biotechnologies has 5 investors. Key investors include HHS, OSANG Healthcare, FuturePlay, Coolidge Corner Investment, and KBD Capital.
Kryptos Biotechnologies operates through Kryptos Biotechnologies, Inc..